PCM
DERM icon

Prelude Capital Management’s Journey Medical DERM Stock Holding History

Prelude Capital Management’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Sell
21,905
-7,989
-27% -$45.6K 0.01% 1034
2026
Q1 		$140K Buy
+29,894
New +$232K 0.01% 991
2024
Q2 		– Sell
-15,060
Closed -$55.4K – 1275
2024
Q1 		$55.4K Buy
+15,060
New +$65.5K ﹤0.01% 1250

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAIM
Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Prelude Capital Management's DERM Position: Q2 2026 in Review

Prelude Capital Management reduced its Journey Medical (DERM) stake by 27% in Q2 2026, selling an estimated $45.6K and leaving 21,905 shares worth $155K. The position accounts for 0.01% of the portfolio, ranked #1034.

Prelude Capital Management first reported a position in DERM in Q1 2024 and has held it in 3 quarters since. 71 funds tracked by Wall St. Rank hold DERM as of Q2 2026.

  • Prelude Capital Management held 21,905 shares of Journey Medical worth $155K as of Q2 2026.
  • Prelude Capital Management sold 7,989 Journey Medical shares in Q2 2026, an estimated $45.6K.
  • Journey Medical made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1034 holding.
  • Prelude Capital Management first reported a position in Journey Medical in Q1 2024 and has held it in 3 quarters since.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.